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SHORT REPORT
Lupus anticoagulant associated with transient severe
factor X deficiency: a report of two patients presenting
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Summary. Acquired factor X (FX) deficiency is rare, but has
been reported in diverse disease states, including systemic
amyloidosis and respiratory infections. FX deficiency asso-
ciated with lupus anticoagulant (LA) and a bleeding dia-
thesis has not been previously reported. We report two
patients both of whom presented with a severe bleeding
diathesis after a preceding respiratory infection due to iso-
lated FX deficiency associated with a LA. The FX deficiency
and LA were transient. We conclude that patients with LA
may rarely present with severe acquired FX deficiency. This
may be another mechanism whereby patients with anti-
phospholipid antibodies present with bleeding complica-
tions.
Keywords: lupus anticoagulant, acquired factor X defici-
ency, bleeding disorder/bleeding diathesis, respiratory
infection.
Isolated factor X (FX) deficiency is rare and is associated
with a bleeding tendency. The congenital form is inherited
in an autosomal recessive manner (Peyvandi & Mannucci,
1999). Acquired FX deficiency has been frequently reported
in patients with systemic amyloidosis (Choufani et al,
2001), and sporadically in association with respiratory
infections (Peuscher et al, 1979; Currie et al, 1984;
Mulhare et al, 1991) or other disorders, or as an idiopathic
finding (Lankiewicz & Bell, 1992).
Lupus anticoagulant (LA) is an antibody that is directed
against phospholipid–protein complexes. As a result, phos-
pholipid-dependent clotting tests, such as the activated
partial thromboplastin time (aPTT), are prolonged. Pro-
thrombin and b2-glycoprotein 1 are the most commonly
recognized target protein antigens for antiphospholipid
antibodies, although other proteins such as proteins C or
S have been occasionally found to be the target antigen
(Arnout, 2001). Recently, antibodies directed against factor
XII (FXII) have been identified, leading to decreased FXII
levels (Jones et al, 2000). Most patients with LA do not bleed
abnormally, except for a small subset that has a specific
deficiency of factor II (LA–hypoprothrombinaemia syn-
drome) (Lee et al, 1996). The LA–hypothrombinaemia
syndrome reflects formation of prothrombin–antiprothrom-
bin immune complexes that are cleared from circulation
(Edson et al, 1984; Galli & Barbui, 1999).
Here we report two patients who presented with a severe
bleeding diathesis due to isolated FX deficiency associated
with a LA. To our knowledge, no similar patients have been
previously reported. This may be an alternative mechanism
by which patients with LA may occasionally present with
bleeding complications.
MATERIALS AND METHODS
All prothrombin time (PT) assays were performed using
recombinant relipidated tissue factor (InnovinTM; Dade
Behring, Deerfield, IL, USA). aPTT assays were performed
using partial thromboplastins, including automated aPTT or
Platelin L (Organon Teknika, Durham, NC, USA), or an
LA-sensitive in-house aPTT reagent in which 0Æ075%
aluminium silicate was used as an activator, and the
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chloroform extract of acetone-dried rabbit brain thrombo-
plastin as the phospholipid source (Edson et al, 1984). The
measurement of specific clotting factor activity was per-
formed by one-stage clotting assays (PT based for FII, FV,
FVII and FX, and aPTT based for FVIII, FIX, FXI and FXII),
using a mixture of the appropriate factor-deficient substrate
plasma and the test plasma with 1/10, 1/20, 1/40 and
1/80 dilutions. Dilute Russell viper venom time (dRVVT)
assays, including screening, mixing and confirmatory
procedures, were performed using reagents from Ameri-
can Diagnostica (Greenwich, CT, USA) or Sigma Diagnos-
tics (St Louis, MO, USA). A mixing assay (1:1) was used
to screen for neutralizing antibodies to FX, monitored by
assay of FX coagulation activity (FX:C), both immediately
after mixing and following 1 or 2 h incubation at 37C.
Additionally, we screened for non-neutralizing antibodies
to FX, using FX-crossed immunoelectrophoresis (Edson
et al, 1984).
Table I.
(A) Summary of selected laboratory test results.
Parameter Patient 1 Patient 2 Reference range
Platelets (·109/l) 223 207 150–450
APTT (s) 63Æ0 76Æ3 21–33
PT (s) 110Æ7 45Æ5 8Æ4–12
TT (s) 17 18Æ8 18–25
Factor II:C 123% 97% 70–130%
Factor V:C 68% 103% 70–130%
Factor VII:C 85% 72% 70–130%
Factor VIII:C 408% 260% 75–135%
Factor IX:C Not done 144% 75–135%
Factor X:C < 3% 3% 70–130%
Factor XI:C 95% Not done 65–150%
Factor XII:C 55% Not done 65–200%
ESR (mm/h) 68 76 0–30
Fibrinogen (g/l) 4Æ64 5Æ96 1Æ7–3Æ7
D-dimer (ng/ml) 250 500–1000 0–300
PT, prothrombin time; aPTT, activated partial thromboplastin time; TT, throm-
bin time; ESR, erythrocyte sedimentation rate.
(B) Summary of laboratory data to identify lupus anticoagulant
Laboratory test
Patient 1 Patient 2
PNP Patient 1 Patient:PNP (1:1) PNP Patient 2 Patient:PNP (1:1)
aPTT using aluminium silicate (s) 30Æ2 78Æ8 42Æ7 28Æ1 84Æ8 35Æ9
aPTT using Organon Teknika (s) 31Æ3 60Æ4 42Æ3
Platelet neutralization test (aPTT based,
using aluminium silicate)
Plasma (s) 30Æ5 80Æ8 28Æ8 81Æ9
+ Buffer control (s) 31Æ5 46Æ6 30Æ7 63Æ8
+ Freeze-thawed platelets (s) 28Æ6 42Æ8 31Æ3 64Æ7
Staclot LA (Diagnostica Stago, Parsippany, NJ, USA)
Baseline aPTT (s) 125
Hexagonal-phase aPTT (s) 63
DRVVT
Screen (s); patient/PNP ratio
(normal ratio < 1Æ2)
35Æ1 > 150; > 4Æ27
1:4 mix screen (s); patient/PNP ratio
(normal ratio < 1Æ2)
35Æ5 117Æ3; 3Æ34
Confirm (s); normalized ratio
(normal ratio < 1Æ2)
29Æ7 53Æ5; 2Æ37
Prothrombin time (s) 9Æ7 110Æ7 30Æ2
DRVVT, dilute Russell viper venom time; PNP, pooled normal plasma.
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CASE REPORT
Patient 1. A 62-year-old man presented to his local
hospital in March 2001 with a 2-d history of progressive
swelling and bruising in his right knee and calf, and
haematuria. He had a 3-month history of a dry cough.
There was no personal or family history of bleeding diathe-
sis. Laboratory studies showed: haemoglobin 10Æ7 g/dl,
PT > 100 s and aPTT 79 s. The prolonged PT and PTT did
not correct on 1:1 mixing with normal plasma. Chest
radiograph revealed a right middle lobe infiltrate. His
condition worsened, with increasing right leg swelling,
development of numbness and weakness of the right foot, in
conjunction with a declining haemoglobin (nadir 5Æ2 g/dl).
He was then transferred to our centre for further manage-
ment.
On examination, the patient had large ecchymotic lesions
in both axillary folds, over the right infra-axillary chest wall
and the right calf. His right thigh was swollen and the right
calf was tense. He had no sensation below his right ankle
and was unable to dorsi- or plantar-flex his right ankle or
toes.
Pertinent laboratory results are summarized in Table IA.
Additional laboratory tests were consistent with the pres-
ence of a potent coagulation inhibitor that fulfilled criteria
for a strong LA (Table IB), with associated FX deficiency. A
mixing study of the prolonged PT demonstrated definite
inhibition. The patient’s plasma inhibited the assay systems
for coagulation factors II, V, VII and VIII but, using four
serial dilutions, the activity progressively increased into the
normal range. However, no FX (< 3%) activity could be
demonstrated at any dilution. The FX inhibitor screening
assay was negative, as was the Bethesda assay for a FX
inhibitor [< 1 Bethesda Unit (BU)]. Crossed immuno-elec-
trophoresis (CIEP) revealed no evidence of FX–anti-FX
immune complexes.
An emergency four-compartment fasciotomy was per-
formed for a diagnosis of calf compartment syndrome.
Because the patient refused blood products (Jehovah’s
Witness), he was administered recombinant FVIIa (rFVIIa;
NovoSevenTM) 120 lg/kg intravenously prior to surgery,
followed by 90 lg/kg every 2 h for 12 h. Additionally, he
received prednisone 100 mg daily and the macrolide
antibiotic azithromycin.
Subsequently, FX activity recovered to normal levels over
the course of about 1 week (Fig 1). No additional bleeding
occurred. Evaluations for monoclonal paraproteinaemia
and lung cancer were negative, as were bacteriological
studies of blood and sputum. An LA screen at 8 weeks
revealed that the inhibitor was no longer present. Anti-
cardiolipin and beta-2-glycoprotein antibodies were negat-
ive at this time. The patient had persistent foot drop and
sensory loss in his right foot on later follow-up.
Patient 2. A 59-year-old man presented in October 1997
with a 4-d history of headache, fever, chills and mild
epistaxis, and a 1-d history of gross haematuria and back
pain. Additionally, he complained of dry cough, anorexia
and fatigue. There was no personal or family history of
excessive bleeding. On physical examination, his abdomen
was distended and tender. Pertinent laboratory tests are
summarized in Table IA. He was administered vitamin K
and fresh-frozen plasma with only minor correction of PT
and aPTT. Over the ensuing 2 d, his haemoglobin declined
to 7Æ7 g/dl. Computerized tomography (CT) of the chest and
abdomen revealed mediastinal adenopathy, bilateral pleural
effusion, large retroperitoneal bleed, right kidney obstruc-
tion, and a filling defect (presumably haematoma) in the left
renal pelvis and the urinary bladder. Serum protein
electrophoresis did not demonstrate any monoclonal para-
proteins. The bacteriological studies of blood and urine were
negative.
aPTT mixing studies demonstrated an inhibitor, with a
positive platelet neutralization procedure, indicating the
presence of a moderate LA (Table IB). FX inhibitor screening
assay demonstrated no immediate or progressive inhibition
of FX activity in normal plasma. On the FX antigen CIEP,
there was no evidence of FX–anti-FX immune complexes.
The patient was treated with packed red blood cell
transfusions, fresh-frozen plasma, vitamin K and ceftriaxone
with good clinical result. At dismissal on d 8, his PT was
16 s and aPTT 37 s. Cystoscopy revealed no evidence of
tumour, and lymph node biopsies from the mediastinum
were consistent with a reactive process. He made an
uneventful recovery.
Fig 1. Factor X activity over time for Patient
1. The arrow represents the day of adminis-
tration of rFVIIa. The apparent transient rise
in FX:C at that time probably reflects short-
ening of the PT due to high concentrations of
rFVIIa in the sample.
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DISCUSSION
In this report, we present the clinical data of two patients
with a transient, postinfectious, isolated, acquired FX
deficiency, associated with LA, which in both patients
presented with a serious bleeding diathesis. In patient 1,
rFVIIa was effective in controlling bleeding during fasciot-
omy, similar to that found by Boggio and Green (2001) in
amyloid-associated FX deficiency.
We could not demonstrate free, circulating FX neut-
ralizing antibodies, either immediately after mixing or
following a 1–2 h incubation at 37C, in either patient.
Furthermore, we were unable to establish the presence of
circulating non-neutralizing FX–anti-FX immune com-
plexes. We, therefore, speculate that all of the anti-FX
antibody was utilized in vivo, with accelerated immune-
mediated clearance of FX. This syndrome may thus be
akin to LA–hypoprothrombinaemia syndrome, which is
due to the formation of a non-neutralizing antiprothrom-
bin antibody, and can also be a transient postinfectious
phenomenon (Lee et al, 1996). Transient FX deficiency
may be another mechanism whereby patients with
antiphospholipid antibodies develop bleeding complica-
tions. Additionally, this report highlights the varied
spectrum of antibody specificity or crossreactivity of lupus
anticoagulant.
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